Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria.
BACKGROUND
The prognosis for patients with primary hyperoxaluria has been ominous, with the expectation of renal failure, poor results with transplantation, and early death.


METHODS
We studied the long-term effects of orthophosphate and pyridoxine therapy in 25 patients with primary hyperoxaluria who were treated for an average of 10 years (range, 0.3 to 26). Their mean age at the start of treatment was 12 years (median, 6; range, 0.5 to 32). We also studied the effect of orthophosphate and pyridoxine on urinary supersaturation with calcium oxalate, crystal inhibition using a seeded growth system, and crystal formation using scanning electron microscopy in 12 patients during three-day stays in the clinical research center.


RESULTS
The mean (+/- SD) glomerular filtration rate at the start of treatment was 91 +/- 26 ml per minute per 1.73 m2. The median decline in glomerular filtration rates was 1.4 ml per minute per 1.73 m2 of body-surface area per year. The actuarial survival free of end-stage renal disease was 96, 89, 74, and 74 percent of 5, 10, 15, and 20 years, respectively. Treatment with orthophosphate and pyridoxine reduced urinary supersaturation with calcium oxalate from 8.3 +/- 3.0 to 2.1 +/- 1.7 kJ per mole at 38 degrees C (P < 0.001), increased the inhibition of calcium oxalate formation from 63 +/- 11 to 108 +/- 10 inhibitor units per 24 hours (P < 0.001), and improved the crystalluria score from 2.6 +/- 0.3 to 0.6 +/- 0.1 (P < 0.001).


CONCLUSIONS
Treatment of patients with primary hyperoxaluria with orthophosphate and pyridoxine decreases urinary calcium oxalate crystallization and appears to preserve renal function.
Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905.
D S
DS
Milliner
J T
JT
Eickholt
E J
EJ
Bergstralh
D M
DM
Wilson
L H
LH
Smith
D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D002129:Calcium Oxalate / Q000652:urine; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006959:Hyperoxaluria / Q000188:drug therapy* / Q000503:physiopathology; D007223:Infant; D007676:Kidney Failure, Chronic / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000627:therapeutic use*; D011379:Prognosis; D011736:Pyridoxine / Q000627:therapeutic use*
D010710:Phosphates; D002129:Calcium Oxalate; D011736:Pyridoxine